retatrutide benefits clinical trial retatrutide Eli Lilly's shows promising weight loss results in phase 3 Diagram showing the mechanism of

If your BMI and health history make you a candidate, discuss your options with a licensed healthcare provider to determine whether this or another weight management program is appropriate for you

GLP-1 receptor agonists: an updated review of head-to-head clinical studies

Lillys triple agonist retatrutide delivered weight loss of up to an average of 71.2 lbs in first successful Phase 3 trial. Retrieved 2026-07-03

For more significant excess skin, a surgical consult is often the most effective path

The decision to continue or modify GLP-1 treatment should be made collaboratively, weighing the benefits of metabolic control against the distress caused by hair loss

The number one reason patients may experience headaches on these medications is because they forget to hydrate throughout the day, says Agrawal